REFERENCES
- den Brinker M, Wit F, Wertheim-van Dillen P, et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS. 2000;14:2895–2902.
- Wit F, Weverling G, Weel J, Jurriaans S, Lange J. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis. 2002;186:23–31.
- Puoti M, Torti C, Ripamonti D, et al. Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome. J Acquir Immune Defic Syndr. 2003;32:259–267.
- Kontorinis N, Dieterich D. Hepatotoxicity of antiretroviral therapy. AIDS Rev. 2003;5:36–43.
- Martinez E, Blanco JL, Arnaiz J, et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS. 200115: 1261–1268.
- Martin-Carbonero L, NOriez M, González-Lahoz JM, Soriano V. Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine. HIV Clin Trials. 2003;4(2):115–120.
- Sulkowski M, Thomas D, Chaisson R, Moore R. Hepato-toxicity associated with antiretroviral therapy in adults in-fected with HIV and the role of hepatitis C or B virus infection. JAMA. 2000;283:74–80.
- Barditch-Crovo P, Deeks S, Collier A, et al. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in HIV-infected adults. Antimicrob Agents Chemother. 2001;45:2733–2739.
- Antoniou T, Park-Wyllie L, Tseng A. Tenofovir: a nucleotide analog for the management of HIV infection. Pharmaco-therapy. 2003;23:29–43.
- Gallant J, Deresinski S. Tenofovir disoproxil fumarate. Clin Infect Dis. 2003;37:944–950.
- Kearney B, Flaherty J, Shah J. Tenofovir disoproxil fuma-rate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet. 2004;43:595–612.
- Nunez M, Puoti M, Camino N, Soriano V. Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future. Clin Infect Dis. 2003;37(12):1678–1685.
- Klein M, Campeol N, Lalonde R, Brenner B, Wainberg M. Didanosine, interferon-alfa and ribavirin: a highly synergis-tic combination with potential activity against HIV-1 and hepatitis C virus. AIDS. 2003;17:1001–1008.
- Butt A. Fatal lactic acidosis and pancreatitis associated with ribavirin and didanosine therapy. AIDS Read. 2003;13:344–348.
- Moreno A, Quereda C, Moreno L, et al. High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin. Antivir Ther. 2004;9:133–138.
- Barrios A, Garcia-Benayas T, Gonzalez-Lahoz J, Soriano V. Tenofovir-related nephrotoxicity in HIV-infected pa-tients. AIDS. 2004;18:960–963.
- James C, Steinhaus M, Szabo S, Dressier R. Tenofovir-related nephrotoxicity: case report and review of the litera-ture. Pharmacotherapy. 2004 ;24:415–418.
- Peyriere H, Reynes J, Rouanet I, et al. Renal tubular dys-function associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr. 2004;35:269–273.
- Verhelst D, Monge M, Meynard JL, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis. 2002;40:1331–1333.
- Margot N, Miller N. In vitro anti-HIV combination studies of ribavirin with tenofovir and other nucleoside analogs. In: Program and abstracts of the 2nd IAS Conference; 2003; Paris. Abstract 980.
- Nunez M, Maida I, Berclun M, on behalf of the PRESCO Team. Efficacy and safety of pegylated interferon alpha-2a plus ribavirin for the treatment of hepatitis C in HIV-coinfected patients: the PRESCO trial. In: Program and abstracts of the 44th ICAAC; 2004; Washington, DC. Ab-stract V–1148.